害怕疾病进展和复发在多发性硬化症:一个系统的范围审查审查
Arashk Mallahzadeh1,2, Tahereh Fereydoonnezhad3, Lynne V Gauthier4
1School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Frontiers in psychiatry
|November 28, 2025
概括
害怕复发和疾病进展显著影响多发性硬化症 (MS) 患者,影响他们的生活质量. 通过量身定制的干预措施来解决这些恐惧对于改善患者福祉至关重要.
科学领域:
- 神经学 神经学
- 心理学 心理学 心理学
- 公共卫生 公共卫生
背景情况:
- 多发性硬化症 (MS) 是一种慢性中枢神经系统疾病,影响年轻成年人.
- 关于复发和残疾的不确定性会导致心理痛苦,并降低MS患者的生活质量.
研究的目的:
- 在多发性硬化症 (MS) 中系统地审查复发和疾病进展的恐惧的流行,决定因素和后果.
主要方法:
- 一个系统的范围审查,遵守PRISMA-ScR指南.
- 在PubMed,Scopus和Web of Science中搜索了关于对MS复发或进展的恐惧的原始英语研究.
- 包括没有人口统计或疾病阶段限制的研究;进行数据提取和质量评估.
主要成果:
- 13项研究符合资格标准,使用恐惧复发或进展等级.
- 多发性硬化患者对进展的恐惧范围从最小到严重,担心独立性和外部帮助.
- 增加的恐惧与更高的疲劳,抑郁,压力,健康焦虑和更低的生活质量相关.
结论:
- 恐惧复发和进展是普遍存在的,并显著影响着MS患者.
- 未来的研究应该优先评估心理支持和应对策略等干预措施.
- 需要量身定制的干预措施来帮助MS患者管理疾病进展和复发的恐惧.
相关概念视频
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
382
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
382


